WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach-Reference-Cited by-同舟云学术

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach

Published:2016-12-29 Issue:3 Volume:49 Page:431-437
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Otto Wolfgang,Breyer Johannes^ORCID,Herdegen Sonja,Eder Fabian,Bertz Simone,May Matthias,Mayr Roman,Lausenmeyer Eva M.,Denzinger Stefan,van Rhijn Bas W. G.,Burger Maximilian,Hartmann Arndt

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/content/pdf/10.1007/s11255-016-1491-9.pdf

Reference29 articles.

1. Baum B, Settleman J, Quinlan MP (2008) Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19:294–308

2. Shook D, Keller R (2003) Mechanisms, mechanics and function of epithelial–mesenchymal transitions in early development. Mech Dev 120:1351–1383

3. Tarin D (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996–6001

4. McConkey DJ, Lee S, Choi W et al (2010) Molecular genetics of bladder cancer: emerging mechanisms of tumour initiation and progression. Urol Oncol Semin Invest 28:429–440

5. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy;Clinical Genitourinary Cancer;2024-12

2. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

3. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study;Investigative and Clinical Urology;2024

4. The role of cell adhesion molecules in the progression of bladder urothelial carcinomas;Romanian Journal of Morphology and Embryology;2022-09-09

5. Non-muscle invasive bladder cancer biomarkers beyond morphology;Frontiers in Oncology;2022-08-03